Pharmacoeconomic evaluation of the effectiveness of therapy for metastatic colorectal cancer
Objective: to perform a pharmacoeconomic evaluation of the effectiveness of therapies for metastatic colorectal cancer (mCRC) based on real practical data on medical help for patients with this disease.Material and methods. The authors performed a comparative cost-effectiveness analysis and the calc...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IRBIS LLC
2021-10-01
|
| Series: | Фармакоэкономика |
| Subjects: | |
| Online Access: | https://www.pharmacoeconomics.ru/jour/article/view/546 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849696834980675584 |
|---|---|
| author | Yu. Yu. Petukhova E. V. Eliseeva M. V. Volkov O. N. Li A. G. Petukhova |
| author_facet | Yu. Yu. Petukhova E. V. Eliseeva M. V. Volkov O. N. Li A. G. Petukhova |
| author_sort | Yu. Yu. Petukhova |
| collection | DOAJ |
| description | Objective: to perform a pharmacoeconomic evaluation of the effectiveness of therapies for metastatic colorectal cancer (mCRC) based on real practical data on medical help for patients with this disease.Material and methods. The authors performed a comparative cost-effectiveness analysis and the calculation of resource consumption in the application of several options of chemotherapy for mCRC: FOLFOX, FOLFIRI, and FOLFOXIRI; targeted therapy: FOLFOX + bevacizumab, FOLFOX + panitumumab, FOLFIRI + cetuximab, FOLFIRI + aflibercept, regorafenib monotherapy.Results. The cost-effectiveness parameter, calculated as a ratio of the cost of therapy to the median survival without progression, for chemotherapeutic schemes varied from 108 to 167 thousand rubles and for the targeted therapy schemes – from 223 to 930 thousand rubles. The calculation of resource consumption showed that in the case of a limited budget, 100% of patients can be treated by FOLFOX scheme, or 26% of patients by FOLFOX + panitumumab, or 47% of patients by FOLFOX + bevacizumab; and 100% of patients by FOLFIRI scheme or 11.5% of patients by FOLFIRI + cetuximab (aflibercept). Besides, it was established that in the case of a similar budget, 100% of patients with mCRC can be treated by chemotherapy schemes or a limited number of patients with regorafenib.Conclusion. The cost of targeted therapy significantly exceeds the cost of chemotherapeutic schemes. Still, considering the gross domestic product per capita in the Russian Federation, they can be an economically feasible investment and the optimum option of therapy |
| format | Article |
| id | doaj-art-01370652822345b69df61b39e21c5e09 |
| institution | DOAJ |
| issn | 2070-4909 2070-4933 |
| language | Russian |
| publishDate | 2021-10-01 |
| publisher | IRBIS LLC |
| record_format | Article |
| series | Фармакоэкономика |
| spelling | doaj-art-01370652822345b69df61b39e21c5e092025-08-20T03:19:20ZrusIRBIS LLCФармакоэкономика2070-49092070-49332021-10-0114329129810.17749/2070-4909/farmakoekonomika.2021.081354Pharmacoeconomic evaluation of the effectiveness of therapy for metastatic colorectal cancerYu. Yu. Petukhova0E. V. Eliseeva1M. V. Volkov2O. N. Li3A. G. Petukhova4Pacific State Medical University; Primorsky Regional Oncological DispensaryPacific State Medical UniversityPrimorsky Regional Oncological DispensaryPacific State Medical UniversityPacific State Medical UniversityObjective: to perform a pharmacoeconomic evaluation of the effectiveness of therapies for metastatic colorectal cancer (mCRC) based on real practical data on medical help for patients with this disease.Material and methods. The authors performed a comparative cost-effectiveness analysis and the calculation of resource consumption in the application of several options of chemotherapy for mCRC: FOLFOX, FOLFIRI, and FOLFOXIRI; targeted therapy: FOLFOX + bevacizumab, FOLFOX + panitumumab, FOLFIRI + cetuximab, FOLFIRI + aflibercept, regorafenib monotherapy.Results. The cost-effectiveness parameter, calculated as a ratio of the cost of therapy to the median survival without progression, for chemotherapeutic schemes varied from 108 to 167 thousand rubles and for the targeted therapy schemes – from 223 to 930 thousand rubles. The calculation of resource consumption showed that in the case of a limited budget, 100% of patients can be treated by FOLFOX scheme, or 26% of patients by FOLFOX + panitumumab, or 47% of patients by FOLFOX + bevacizumab; and 100% of patients by FOLFIRI scheme or 11.5% of patients by FOLFIRI + cetuximab (aflibercept). Besides, it was established that in the case of a similar budget, 100% of patients with mCRC can be treated by chemotherapy schemes or a limited number of patients with regorafenib.Conclusion. The cost of targeted therapy significantly exceeds the cost of chemotherapeutic schemes. Still, considering the gross domestic product per capita in the Russian Federation, they can be an economically feasible investment and the optimum option of therapyhttps://www.pharmacoeconomics.ru/jour/article/view/546colorectal cancerchemotherapytargeted therapycost-effectiveness ratio |
| spellingShingle | Yu. Yu. Petukhova E. V. Eliseeva M. V. Volkov O. N. Li A. G. Petukhova Pharmacoeconomic evaluation of the effectiveness of therapy for metastatic colorectal cancer Фармакоэкономика colorectal cancer chemotherapy targeted therapy cost-effectiveness ratio |
| title | Pharmacoeconomic evaluation of the effectiveness of therapy for metastatic colorectal cancer |
| title_full | Pharmacoeconomic evaluation of the effectiveness of therapy for metastatic colorectal cancer |
| title_fullStr | Pharmacoeconomic evaluation of the effectiveness of therapy for metastatic colorectal cancer |
| title_full_unstemmed | Pharmacoeconomic evaluation of the effectiveness of therapy for metastatic colorectal cancer |
| title_short | Pharmacoeconomic evaluation of the effectiveness of therapy for metastatic colorectal cancer |
| title_sort | pharmacoeconomic evaluation of the effectiveness of therapy for metastatic colorectal cancer |
| topic | colorectal cancer chemotherapy targeted therapy cost-effectiveness ratio |
| url | https://www.pharmacoeconomics.ru/jour/article/view/546 |
| work_keys_str_mv | AT yuyupetukhova pharmacoeconomicevaluationoftheeffectivenessoftherapyformetastaticcolorectalcancer AT eveliseeva pharmacoeconomicevaluationoftheeffectivenessoftherapyformetastaticcolorectalcancer AT mvvolkov pharmacoeconomicevaluationoftheeffectivenessoftherapyformetastaticcolorectalcancer AT onli pharmacoeconomicevaluationoftheeffectivenessoftherapyformetastaticcolorectalcancer AT agpetukhova pharmacoeconomicevaluationoftheeffectivenessoftherapyformetastaticcolorectalcancer |